Latest Articlesddd
Novartis Has More Promising Data from Their Phase 3 Gene Therapy Trial with AveXis AveXis Inc., …
Gilead and insitro Collaborate to Discover and Develop Novel Therapies for NASH using ISH Gilead Sciences …
Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at …
Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (
Regeneron and Alnylam Agreement Will Benefit Both So Why the Sell-Off? Regeneron Pharmacueticals Founded, and led …
The Amgen/Novartis Story In May 2018 Amgen (AMGN) & Novartis (
Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary …
Sangamo’s Stock Price Soars Sangamo Therapeutics’ (SGMO) stock soared more than 52% in pre-market trading following …
The Market is Outperforming Today. There is important news today about Novartis; part of which we …
Following Seattle Genetics' (SGEN) and Astellas Pharma's announcement of positive results, from pivotal trial of the conjugated monoclonal antibody …
The uncontrolled blowing toxic wind contaminates this country’s environment, it brings down the oversold scientifically solid …
While waiting for Mueller’s report we stopped speculating on the stocks in what we saw as …
Governor Cooper to cut ribbon on bluebird bio facility Bluebird bio (BLUE) announced today, in its …
Biogen’s (BIIB) decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE which is designed …
News We Loved to Hear The First and Only Approval of a Specific Product for Postpartum …
The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week …
Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio …
Atossa Genetics (ATOS) announced that the FDA has issued a “Safe to Proceed” letter under their “expanded …
We love to read news about gene therapy as it is the only possibility for curing …
Thanks to abundant cabozantinib sales’ revenues Exelixis (EXEL) is advancing a new generation of its medicines …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
